Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860787 | 0.90 | SYK (0.57) | MAPTLMNASMN1; SMN2SYKSLC1A3 | |
| SCHEMBL24593936 | 0.90 | SYK (0.57) | MAPTLMNASMN1; SMN2SYKSLC1A3 | |
| SCHEMBL16533444 | 0.87 | LMNA (0.60) | MAPTLMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL16269962 | 0.85 | SYK (0.58) | MAPTLMNASMN1; SMN2SYKSLC1A3 | |
| SCHEMBL16269959 | 0.85 | MAPT (0.53) | MAPTLMNASMN1; SMN2SYKSLC1A3 | |
| SCHEMBL565994 | 0.84 | SYK (0.47) | MAPTLMNASMN1; SMN2SYKHTT | |
| SCHEMBL736556 | 0.84 | L3MBTL1 (0.57) | MAPTLMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL734006 | 0.84 | L3MBTL1 (0.57) | MAPTLMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL734005 | 0.84 | L3MBTL1 (0.57) | MAPTLMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL13480455 | 0.84 | SYK (0.66) | MAPTLMNASMN1; SMN2SYKSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING S.P.A. (IT) | 2011-05-26 | — | — | US | disclosed |
| EP-2149568-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | Bracco Imaging S.p.A (IT) | 2010-02-03 | — | — | EP | disclosed |
| WO-2010010080-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | MMP9, MMP1, MMP2 | MAPT 2743/4885LMNA 584/4885SMN1; SMN2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.